Knowledge discovery through Neuroscience Data Integration

In the past few years, wearable devices that can collect medically relevant data has formed a global market which is projected to reach $12.1 billion by 2021, with the US being the largest market. Such an exponential rise in data-generating devices naturally goes together with the astronomical growth of healthcare data.

In this new era it is consumers who directly collect data about health or disease management through digital health technologies. By sifting through these data, data scientists are in hot pursuit of so-called "digital biomarkers", or signatures of health-related conditions, which ultimately are hoped to be able to explain, influence or predict health-related outcomes.

Of particular interest are those digital biomarkers that can help in the area of CNS-related drug discovery, as diseases like Alzheimer's continue to be difficult to develop effective drugs for.

The subject is highly relevant to MetaCell, and recently our CEO Stephen Larson interviewed Dan Karlin, a psychiatrist, former drug developer for Pfizer, currently General Manager of HealthMode.

Download the full article by filling out the form on this page.

Download Article